Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Web Exclusives

Gastrointestinal Cancers

Progression-Free Survival Improved in Patients with HER2-Negative Recurrent or Advanced Gastric or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy

Gastrointestinal Cancers

Nivolumab Combined with Chemotherapy Improves Survival Outcome in Patients with Advanced Gastric/Esophageal Cancers

Gastrointestinal Cancers

Second-Line Pembrolizumab Therapy Conveys Survival Benefit in Patients with Advanced Esophageal Cancer

Gastrointestinal Cancers

ASCO Clinical Practice Guidelines for Clinician Management of Patients with Advanced Esophageal Cancer

Gastrointestinal Cancers

CheckMate 648 Study Data Indicate Improved Overall Survival for Patients with Advanced Esophageal Squamous-Cell Carcinoma Treated with Nivolumab and Ipilimumab or Chemotherapy

Gastrointestinal Cancers

Immune Checkpoint Analysis in Gastric Adenocarcinoma

Gastrointestinal Cancers

Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer Demonstrates Clinical Efficacy

Meeting Highlights

Multiple Myeloma, ASCO Highlights

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Oncology Update

Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer

Meeting Highlights

Biosimilars, ASCO Highlights

Chase Doyle

Page 3 of 41
Results 21 - 30 of 410